Table 1 Participant baseline characteristics in four cohorts
From: Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer
Characteristic | TC (n = 621) | EVC1 (n = 112) | EVC2 (n = 87) | EVC3 (n = 63) |
|---|---|---|---|---|
Age (years) | 54.50 ± 11.51 | 55.19 ± 10.65 | 53.93 ± 11.94 | 54.78 ± 9.83 |
Ultrasound size (cm) | 2.24 ± 1.06 | 2.26 ± 1.12 | 2.17 ± 1.21 | 2.22 ± 0.98 |
BMI | ||||
 <25 | 237 (38.16%) | 36 (32.14%) | 26 (29.89%) | 21 (33.33%) |
 25–30 | 172 (27.70%) | 36 (32.14%) | 27 (31.03%) | 22 (34.92%) |
 >30 | 174 (28.02%) | 35 (31.25%) | 32 (36.78%) | 14 (22.22%) |
Not appliable | 38 (6.12%) | 5 (4.46%) | 2 (2.30%) | 6 (9.52%) |
BI-RADS category | ||||
 4A | 172 (27.70%) | 18 (16.07%) | 6 (6.90%) | 13 (20.63%) |
 4B | 144 (23.19%) | 35 (31.25%) | 12 (13.79%) | 21 (33.33%) |
 4C | 133 (21.42%) | 8 (7.14%) | 12 (13.79%) | 18 (28.57%) |
 5 | 172 (27.70%) | 51 (45.54%) | 57 (65.52%) | 11 (17.46%) |
Tumor location | ||||
 UOQ | 130 (20.93%) | 21 (18.75%) | 25 (28.74%) | 31 (49.21%) |
 LOQ | 61 (9.82%) | 12 (10.71%) | 6 (6.90%) | 12 (19.05%) |
 UIQ | 163 (26.25%) | 38 (33.93%) | 25 (28.74%) | 6 (9.52%) |
 LIQ | 66 (10.63%) | 26 (23.21%) | 13 (14.94%) | 13 (20.63%) |
 Central | 201 (32.37%) | 15 (13.39%) | 18 (20.69%) | 1 (1.59%) |
Nuclear grade | ||||
 I | 96 (15.46%) | 5 (4.46%) | 13 (14.94%) | 10 (15.87%) |
 II | 298 (47.99%) | 67 (59.82%) | 49 (56.32%) | 37 (58.73%) |
 III | 227 (36.55%) | 40 (35.71%) | 25 (28.74%) | 16 (25.40%) |
Tumor classification | ||||
 Noninvasive carcinoma | 59 (9.51%) | 4 (3.57%) | 7 (8.05%) | 2 (3.17%) |
Invasive carcinoma | ||||
 NST | 489 (78.74%) | 97 (86.61%) | 71 (81.61%) | 60 (95.24%) |
 ST | 43 (6.92%) | 8 (7.14%) | 6 (6.90%) | 0 (0.00%) |
 Rare carcinoma | 30 (4.83%) | 3 (2.68%) | 3 (3.45%) | 1 (1.59%) |
ER | ||||
 Positive | 451 (72.62%) | 83 (74.11%) | 64 (73.56%) | 35 (55.56%) |
 Negative | 170 (27.38%) | 29 (25.89%) | 23 (26.44%) | 28 (44.44%) |
PR | ||||
 Positive | 402 (64.73%) | 78 (69.64%) | 52 (59.77%) | 42 (66.67%) |
 Negative | 219 (35.27%) | 34 (30.36%) | 35 (40.23%) | 21 (33.33%) |
HER2 | ||||
 Positive | 520 (83.73%) | 34 (30.36%) | 66 (75.86%) | 48 (76.19%) |
 Negative | 101 (16.26%) | 78 (69.64%) | 21 (24.14%) | 15 (23.81%) |
Ki-67 | ||||
 Positive | 514 (82.77%) | 90 (80.36%) | 66 (75.86%) | 47 (74.60%) |
 Negative | 107 (17.23%) | 22 (19.64%) | 21 (24.14%) | 16 (25.40%) |
Surrogate subtype | ||||
 Luminal A-like | 248 (39.94%) | 16 (14.29%) | 6 (6.90%) | 1 (1.59%) |
 Luminal B-like | 216 (34.78%) | 71 (63.39%) | 58 (66.67%) | 39 (61.90%) |
 HER2-overexpression | 127 (20.45%) | 11 (9.82%) | 20 (22.99%) | 15 (23.81%) |
 Triple negative | 30 (4.83%) | 14 (12.50%) | 3 (3.45%) | 8 (12.70%) |
US-ALN | ||||
 Suspicious | 242 (38.97%) | 37 (33.04%) | 44 (50.57%) | 22 (34.92%) |
 Non-suspicious | 379 (61.03%) | 75 (66.96%) | 43 (49.43%) | 41 (65.08%) |
ALN metastasis | ||||
 Positive | 215 (34.62%) | 45 (40.18%) | 35 (40.23%) | 32 (50.79%) |
 Negative | 406 (65.38%) | 67 (59.82%) | 52 (59.77%) | 31 (49.21%) |
